Engineered Exosomes: Revolutionizing Drug Delivery For CNS Disorders – Preclinical Insights From Prisys Biotech

Engineered exosomes are being developed as a drug delivery platform for central nervous system (CNS) disorders. As naturally derived extracellular vesicles, exosomes carry a lipid bilayer, surface proteins inherited from the parent cell, and a size that lets them move through tissue interstitium. That combination supports biocompatibility, low immunogenicity, and the ability to transport proteins, nucleic acids, and other therapeutic cargo. Through bioengineering, exosomes can be optimized to improve drug loading, stability, targeting efficiency, and circulation time.

One of the main advantages of engineered exosomes is their potential to overcome the blood-brain barrier (BBB). Recent preclinical studies have demonstrated successful delivery of therapeutic molecules, including siRNA and miRNA, to the brain in models of Alzheimer's disease, Parkinson's disease, stroke, and other neurological disorders. These advances point to exosome-based therapies that treat the target tissue directly while limiting exposure elsewhere.

Successful clinical translation requires preclinical evaluation, including biodistribution, pharmacokinetics/pharmacodynamics (PK/PD), safety, immunogenicity, and efficacy studies in appropriate animal models. The workstreams are connected: biodistribution determines which organs safety evaluation must cover, and immunogenicity decides whether repeat-dose data can be interpreted at all. Pharmacokinetics (PK) and Pharmacodynamics (PD) are therefore measured in the same animals that carry the efficacy endpoint, which is where non-human primate studies become useful.